SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283156987> ?p ?o ?g. }

Showing items 1 to 100 of ±140 with 100 items per page.

W4283156987 endingPage "100678" @default.
W4283156987 startingPage "100678" @default.
W4283156987 abstract "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) are among the treatments recommended for high-risk ambulatory persons with coronavirus 2019 (COVID-19). Here, we study viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlanivimab in the ACTIV-2 trial (ClinicalTrials.gov: NCT04518410). Viral load by qPCR and viral culture are performed from anterior nasal swabs collected on study days 0 (day of treatment), 1, 2, 3, and 7. Treatment with mAbs results in rapid clearance of culturable virus. One day after treatment, 0 of 28 (0%) participants receiving mAbs and 16 of 39 (41%) receiving placebo still have culturable virus (p < 0.0001). Recrudescence of culturable virus is detected in three participants with emerging mAb resistance and viral RNA rebound. While further studies are necessary to fully define the relationship between shed culturable virus and transmission, these results raise the possibility that mAbs may offer immediate (household) and public-health benefits by reducing onward transmission." @default.
W4283156987 created "2022-06-21" @default.
W4283156987 creator A5002687453 @default.
W4283156987 creator A5007775833 @default.
W4283156987 creator A5010897684 @default.
W4283156987 creator A5010952025 @default.
W4283156987 creator A5019165039 @default.
W4283156987 creator A5022908215 @default.
W4283156987 creator A5024029270 @default.
W4283156987 creator A5024560316 @default.
W4283156987 creator A5027304381 @default.
W4283156987 creator A5032504505 @default.
W4283156987 creator A5035261268 @default.
W4283156987 creator A5036716419 @default.
W4283156987 creator A5038377747 @default.
W4283156987 creator A5039577185 @default.
W4283156987 creator A5042600960 @default.
W4283156987 creator A5045975864 @default.
W4283156987 creator A5059572608 @default.
W4283156987 creator A5060710888 @default.
W4283156987 creator A5067610777 @default.
W4283156987 creator A5074190084 @default.
W4283156987 creator A5082238950 @default.
W4283156987 creator A5084353681 @default.
W4283156987 creator A5086686047 @default.
W4283156987 creator A5088952559 @default.
W4283156987 date "2022-07-01" @default.
W4283156987 modified "2023-10-14" @default.
W4283156987 title "Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection" @default.
W4283156987 cites W3013893137 @default.
W4283156987 cites W3096658347 @default.
W4283156987 cites W3111431752 @default.
W4283156987 cites W3133980772 @default.
W4283156987 cites W3182094313 @default.
W4283156987 cites W3190880275 @default.
W4283156987 cites W3193911193 @default.
W4283156987 cites W3207722453 @default.
W4283156987 cites W4200559902 @default.
W4283156987 cites W4212988737 @default.
W4283156987 cites W4221018597 @default.
W4283156987 cites W4221072241 @default.
W4283156987 cites W4225553089 @default.
W4283156987 cites W4225647476 @default.
W4283156987 doi "https://doi.org/10.1016/j.xcrm.2022.100678" @default.
W4283156987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35793677" @default.
W4283156987 hasPublicationYear "2022" @default.
W4283156987 type Work @default.
W4283156987 citedByCount "9" @default.
W4283156987 countsByYear W42831569872022 @default.
W4283156987 countsByYear W42831569872023 @default.
W4283156987 crossrefType "journal-article" @default.
W4283156987 hasAuthorship W4283156987A5002687453 @default.
W4283156987 hasAuthorship W4283156987A5007775833 @default.
W4283156987 hasAuthorship W4283156987A5010897684 @default.
W4283156987 hasAuthorship W4283156987A5010952025 @default.
W4283156987 hasAuthorship W4283156987A5019165039 @default.
W4283156987 hasAuthorship W4283156987A5022908215 @default.
W4283156987 hasAuthorship W4283156987A5024029270 @default.
W4283156987 hasAuthorship W4283156987A5024560316 @default.
W4283156987 hasAuthorship W4283156987A5027304381 @default.
W4283156987 hasAuthorship W4283156987A5032504505 @default.
W4283156987 hasAuthorship W4283156987A5035261268 @default.
W4283156987 hasAuthorship W4283156987A5036716419 @default.
W4283156987 hasAuthorship W4283156987A5038377747 @default.
W4283156987 hasAuthorship W4283156987A5039577185 @default.
W4283156987 hasAuthorship W4283156987A5042600960 @default.
W4283156987 hasAuthorship W4283156987A5045975864 @default.
W4283156987 hasAuthorship W4283156987A5059572608 @default.
W4283156987 hasAuthorship W4283156987A5060710888 @default.
W4283156987 hasAuthorship W4283156987A5067610777 @default.
W4283156987 hasAuthorship W4283156987A5074190084 @default.
W4283156987 hasAuthorship W4283156987A5082238950 @default.
W4283156987 hasAuthorship W4283156987A5084353681 @default.
W4283156987 hasAuthorship W4283156987A5086686047 @default.
W4283156987 hasAuthorship W4283156987A5088952559 @default.
W4283156987 hasBestOaLocation W42831569871 @default.
W4283156987 hasConcept C119599485 @default.
W4283156987 hasConcept C126322002 @default.
W4283156987 hasConcept C127413603 @default.
W4283156987 hasConcept C12914427 @default.
W4283156987 hasConcept C142462285 @default.
W4283156987 hasConcept C142724271 @default.
W4283156987 hasConcept C156725737 @default.
W4283156987 hasConcept C159047783 @default.
W4283156987 hasConcept C159654299 @default.
W4283156987 hasConcept C203014093 @default.
W4283156987 hasConcept C204787440 @default.
W4283156987 hasConcept C2522874641 @default.
W4283156987 hasConcept C27081682 @default.
W4283156987 hasConcept C2777648638 @default.
W4283156987 hasConcept C2779134260 @default.
W4283156987 hasConcept C3008058167 @default.
W4283156987 hasConcept C524204448 @default.
W4283156987 hasConcept C542903549 @default.
W4283156987 hasConcept C71924100 @default.
W4283156987 hasConcept C761482 @default.
W4283156987 hasConceptScore W4283156987C119599485 @default.
W4283156987 hasConceptScore W4283156987C126322002 @default.